Search results for: 'R&D pharma'

A growing demand for safety and convenience features has amplified the development and adoption of advanced driver assistance systems (ADAS) and autonomous driving (AD) features in passenger vehicles. Original equipment manufacturers seek to adopt level-2-and-above features in their mass-market vehicles to gain a competitive advantage. The United S...

The study discusses the scope of Research & Development in Autonomous, Connectivity, and Electrification (ACE) technologies that can be leveraged to transform the business for automotive manufacturers. As the automotive industry is facing narrowing margins, the need to look to other revenue streams and also keep the customer committed to the brand ...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

The research service primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights into the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalization of key processes ac...

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020. The pharma E&L testing market is ...

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

Countries worldwide are on the verge of reducing their overall greenhouse gas emissions. To achieve their objectives, setting regulatory standards and targets to control emissions from vehicles plays a crucial role. Regional governments adopt Corporate Average Fuel Economy (CAFE) regulation policies/standards to reduce energy consumption, promote s...

19 Nov 2020  |  North America  |  Market Research

Strategic Analysis of the Fiat Chrysler Automobiles and PSA Group Merger

With $170 Billion in Revenue, 8.5 Million in Vehicle Sales, $6.5 Billion in R&D Potential and $4 Billion in Synergies, the FCA-PSA Merger is Poised to Give Strong Competition to Global Automakers

Infographics

×

The proposed merger between the Fiat Chrysler Automobiles (FCA) and the PSA Group is one of the most significant mergers among automotive original equipment manufacturers (OEMs). The merged company will be called Stellantis and will become the fourth-largest automotive OEM in terms of sales volume. This mega consolidation is driven by the need for ...